[go: up one dir, main page]

HN2009003463A - Derivados de n5-(2-etoxi-etil)-n3-(2- piridinil) -3,5- piperidin-dicarboxamida para usarse como inhibidores de renina - Google Patents

Derivados de n5-(2-etoxi-etil)-n3-(2- piridinil) -3,5- piperidin-dicarboxamida para usarse como inhibidores de renina

Info

Publication number
HN2009003463A
HN2009003463A HN2009003463A HN2009003463A HN2009003463A HN 2009003463 A HN2009003463 A HN 2009003463A HN 2009003463 A HN2009003463 A HN 2009003463A HN 2009003463 A HN2009003463 A HN 2009003463A HN 2009003463 A HN2009003463 A HN 2009003463A
Authority
HN
Honduras
Prior art keywords
piridinil
etoxi
etil
dicarboxamide
piperidin
Prior art date
Application number
HN2009003463A
Other languages
English (en)
Inventor
Fumiaki Yokokawa
Takeru Ehara
Shimpei Kawakami
Osamu Irie
Masaki Suzuki
Yuko Hitomi
Atsushi Toyao
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39926743&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HN2009003463(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HN2009003463A publication Critical patent/HN2009003463A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

EN DONDE R1, R2, R3, R4 Y R5 SON COMO SE DEFINEN EN LA MEMORIA DESCRIPTIVA, PARA UTILIZARSE EN EL DIAGNOSTICO Y EL TRATAMIENTO TERAPEUTICO DE UN ANIMAL DE SANGRE CALIENTE, EN ESPECIAL PARA EL TRATAMIENTO DE UNA ENFERMEDAD (=TRASTORNO) QUE DEPENDA DE LA ACTIVIDAD DE LA RENINA; AL USO DE UN COMPUESTO DE ESTA CLASE EN EL TRATAMIENTO DE UNA ENFERMEDAD QUE DEPENDA DE LA ACTIVIDAD DE LA RENINA; A FORMULACIONES FARMACEUTICAS DE UN COMPUESTO DE ESTA CLASE A UN METODO DE TRATAMIENTO EL CUAL COMPRENDE ADMINISTRAR UN COMPUESTO DE ESTA CLASE, Y A UN METODO PARA SU FABRICACION.
HN2009003463A 2007-06-25 2009-12-22 Derivados de n5-(2-etoxi-etil)-n3-(2- piridinil) -3,5- piperidin-dicarboxamida para usarse como inhibidores de renina HN2009003463A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07012412 2007-06-25
EP07111290 2007-06-28

Publications (1)

Publication Number Publication Date
HN2009003463A true HN2009003463A (es) 2012-12-10

Family

ID=39926743

Family Applications (1)

Application Number Title Priority Date Filing Date
HN2009003463A HN2009003463A (es) 2007-06-25 2009-12-22 Derivados de n5-(2-etoxi-etil)-n3-(2- piridinil) -3,5- piperidin-dicarboxamida para usarse como inhibidores de renina

Country Status (26)

Country Link
US (2) US8383650B2 (es)
EP (2) EP2527338B1 (es)
JP (1) JP5086433B2 (es)
KR (1) KR101238479B1 (es)
CN (1) CN101687847B (es)
AR (1) AR067132A1 (es)
AU (1) AU2008267287B2 (es)
BR (1) BRPI0813900A2 (es)
CA (1) CA2689109A1 (es)
CL (1) CL2008001872A1 (es)
CO (1) CO6251267A2 (es)
CR (1) CR11153A (es)
CU (1) CU23842B1 (es)
EA (1) EA016446B1 (es)
EC (1) ECSP099825A (es)
ES (2) ES2543641T3 (es)
GT (1) GT200900324A (es)
HN (1) HN2009003463A (es)
IL (1) IL202494A0 (es)
MA (1) MA31538B1 (es)
NZ (1) NZ582098A (es)
PE (1) PE20090425A1 (es)
SG (1) SG182223A1 (es)
TN (1) TN2009000530A1 (es)
TW (1) TWI404714B (es)
WO (1) WO2009000811A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0813900A2 (pt) 2007-06-25 2014-12-30 Novartis Ag Derivados de n5-(2-etoxietil)-n3-(2-piridinil)-3,5-piperidinodicarboxa mida para uso como inibidores de renina
US20180048921A1 (en) * 2016-08-12 2018-02-15 Microsoft Technology Licensing, Llc Real-time playback diagnostics

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG44510A1 (en) 1991-12-18 1997-12-19 Schering Corp Imidazolyl or imidazoylalkyl substituted with a four or five membered nitrogen containing heterocyclic ring
IL111176A0 (en) 1993-10-07 1994-12-29 Du Pont Merck Pharma Dipeptide boronic acid inhibitors of trypsin-like enzymes and pharmaceutical compositions containing them
IL123293A (en) 1995-09-07 2003-06-24 Hoffmann La Roche Piperidine derivatives, their preparation and pharmaceutical compositions containing them
EP0862435A4 (en) 1995-11-22 1999-02-03 Merck & Co Inc Inhibitors of farnesyl-protein transferase
AU9206798A (en) 1997-08-28 1999-03-16 Merck & Co., Inc. Pyrrolidine and piperidine modulators of chemokine receptor activity
CA2333554A1 (en) 1998-06-17 1999-12-23 Chu-Baio Xue Cyclic hydroxamic acids as metalloproteinase inhibitors
US6274735B1 (en) 1998-08-10 2001-08-14 Hoffmann-La Roche Inc. Process and intermediates for preparation of substituted piperidines
EP1124822A4 (en) 1998-10-30 2002-04-03 Merck & Co Inc THROMBIN INHIBITORS
WO2000051610A1 (en) 1999-03-02 2000-09-08 Merck & Co., Inc. Pyrrolidine modulators of chemokine receptor activity
AU3386500A (en) 1999-03-02 2000-09-21 Merck & Co., Inc. 3-cyclopropyl and 3-cyclobutyl pyrrolidine modulators of chemokine receptor activity
US6303593B1 (en) 1999-03-02 2001-10-16 Merck & Co., Inc. 3-thienyl and 3-furanyl pyrrolidine modulators of chemokine receptor activity
WO2000063173A1 (en) 1999-04-14 2000-10-26 F. Hoffmann-La Roche Ag Process for the preparation of substituted piperidines
US6197959B1 (en) 1999-04-27 2001-03-06 Hoffmann-La Roche Inc. Piperidine derivatives
US6376672B1 (en) 1999-04-27 2002-04-23 Hoffmann-La Roche Inc. Naphthalenylmethoxypiperidines as renin inhibitors
CZ20023033A3 (cs) 2000-03-17 2003-01-15 Bristol-Myers Squibb Pharma Company Deriváty cyklických beta-aminokyselin jako inhibitory matrixových metaloproteáz a TNF-alfa
FR2811673B1 (fr) 2000-07-17 2002-09-13 Rhodia Chimie Sa Utilisation de composes insatures comprenant un heterocycle comme stabilisants de polymeres halogenes
EP1326619A2 (en) 2000-10-11 2003-07-16 Merck & Co., Inc. Pyrrolidine modulators of ccr5 chemokine receptor activity
WO2002076440A2 (en) 2001-03-23 2002-10-03 Elan Pharmaceuticals, Inc. Methods of treating alzheimer's disease with piperidin derivates
US20030095958A1 (en) 2001-04-27 2003-05-22 Bhisetti Govinda R. Inhibitors of bace
WO2003024899A2 (en) 2001-09-17 2003-03-27 Bristol-Myers Squibb Company CYCLIC HYDROXAMIC ACIDS AS INHIBITORS OF MATRIX METALLOPROTEINASES AND/OR TNF-α CONVERTING ENZYME (TACE)
WO2003031443A1 (en) 2001-10-04 2003-04-17 Morphochem Aktiengesellschaft für kombinatorische Chemie Dual actions antibiotics comprising a oxazoldinone and a quinolone or naphthyridinone moiety
MXPA04010608A (es) 2002-04-29 2004-12-13 Actelion Pharmaceuticals Ltd Derivados de 7-aril-3,9-diazabiciclo(3.3.1)non-6-eno y sus usos como inhibidores de renina en el tratamiento de enfermedades de hipertension, cardiovasculares o renales.
DE60324552D1 (en) 2002-05-20 2008-12-18 Bristol Myers Squibb Co Substituierte cycloalkyl p1' hepatitis c virus inhibitoren
AU2003259131A1 (en) 2002-07-09 2004-01-23 Bristol-Myers Squibb Company Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method
US20040204455A1 (en) 2003-04-10 2004-10-14 Cody Wayne Livingston Piperidine derivative rennin inhibitors
US20040214832A1 (en) 2003-04-10 2004-10-28 Cuiman Cai Piperazine derivative renin inhibitors
CA2521951A1 (en) 2003-04-28 2004-11-11 Actelion Pharmaceuticals Ltd Diazabicyclononene and tetrahydropyridine derivatives as renin inhibitors
CN1972912A (zh) 2003-04-29 2007-05-30 埃科特莱茵药品有限公司 新型3,4－二取代的1,2,3,6－四氢吡啶衍生物
WO2004096803A1 (en) 2003-04-30 2004-11-11 Actelion Pharmaceuticals Ltd Azabicyclononene derivatives
MXPA05011497A (es) 2003-04-30 2005-12-15 Actelion Pharmaceuticals Ltd Derivados de tropano y su uso como inhibidores de la enzima de conversion de angiotensina (ace).
US20060258648A1 (en) 2003-04-30 2006-11-16 Olivier Bezencon 9-Azabicyclo'3.3.1 inon-6-ee derivatives with a heteroatom at the 3-position as renin inhibitors
AU2004233577A1 (en) 2003-05-02 2004-11-11 Actelion Pharmaceuticals Ltd. Diazabicyclononene derivatives
US7144907B2 (en) 2003-09-03 2006-12-05 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
TW200513461A (en) 2003-10-01 2005-04-16 Speedel Experimenta Ag Organische verbindungen
US20080234305A1 (en) 2003-10-09 2008-09-25 Olivier Bezencon Novel Tetrahydropyridine Derivatives
RU2374228C2 (ru) 2003-11-26 2009-11-27 Новартис Аг Производные 4-фенилпиперидина в качестве ингибиторов ренина
AU2004293178B8 (en) 2003-11-26 2009-01-08 Novartis Ag Organic compounds
WO2005070877A1 (en) 2004-01-23 2005-08-04 Speedel Experimenta Ag Diamino alcohols and their use as renin inhibitors
CA2553840A1 (en) 2004-01-23 2005-08-04 Speedel Experimenta Ag Amino alcohol derivatives and their activity as renin inhibitors
WO2005070870A2 (en) 2004-01-23 2005-08-04 Speedel Experimenta Ag Amino alcohol derivatives and their use as renin inhibitors
BRPI0508961A (pt) 2004-03-19 2007-08-14 Speedel Experimenta Ag derivados de 5-amino-4-hidróxi-7-(1h-indolmetil)-8-metilnonamida como inibidores de renina para o tratamento de hipertensão
EP1725530A1 (en) 2004-03-19 2006-11-29 Speedel Experimenta AG Organic compounds
TW200613274A (en) 2004-07-09 2006-05-01 Speedel Experimenta Ag Organic compounds
TW200631929A (en) 2004-12-10 2006-09-16 Speedel Experimenta Ag ω -phenyloctanamides
GB0428250D0 (en) 2004-12-23 2005-01-26 Novartis Ag Organic compounds
GB0428526D0 (en) 2004-12-30 2005-02-09 Novartis Ag Organic compounds
GB0500784D0 (en) 2005-01-14 2005-02-23 Novartis Ag Organic compounds
GB0504850D0 (en) 2005-03-09 2005-04-13 Novartis Ag Organic compounds
EP1856032A1 (en) 2005-03-11 2007-11-21 Speedel Experimenta AG Heterocyclic-substituted alkanamides useful as renin inhibitors
GB0505969D0 (en) 2005-03-23 2005-04-27 Novartis Ag Organic compounds
TW200722424A (en) 2005-03-31 2007-06-16 Speedel Experimenta Ag Substituted piperidines
US20090270380A1 (en) 2005-03-31 2009-10-29 Peter Herold 3,4,5-Substituted Piperidines as Renin Inhibitors
GB0508992D0 (en) * 2005-05-03 2005-06-08 Novartis Ag Organic compounds
GB0510810D0 (en) 2005-05-26 2005-06-29 Novartis Ag Organic compounds
GB0511063D0 (en) 2005-05-31 2005-07-06 Novartis Ag Organic compounds
GB0514203D0 (en) * 2005-07-11 2005-08-17 Novartis Ag Organic compounds
PL1948654T3 (pl) 2005-09-17 2009-12-31 Novartis Ag Pochodne 5-amino-4-hydroksy-7-(imidazo [1,2-a] pirydyn-6-ylometylo)-8-metylononyloamidu i związki pokrewne jako inhibitory reniny do leczenia nadciśnienia
CN101262864A (zh) 2005-09-17 2008-09-10 斯皮德尔实验股份公司 饱和o-杂环取代的烷酰胺
PE20071079A1 (es) * 2005-11-15 2007-12-16 Cytokinetics Inc Compuestos de piperidina como inhibidores de la proliferacion celular
EP2420491B1 (en) * 2005-12-30 2013-07-03 Novartis AG 3 , 5-substitued piperidine compounds as renin inhibitors
EP1816122A3 (en) 2006-01-19 2007-09-19 Speedel Experimenta AG 3,4,5-substituted piperidines as therapeutic compounds
EP1979323A1 (en) 2006-01-30 2008-10-15 Speedel Experimenta AG Process for the stereoselective preparation of alcohols from alpha, beta-insaturated compounds
US20090306062A1 (en) 2006-06-08 2009-12-10 Peter Herold 2,5-Disubstituted Piperidines
GB0611697D0 (en) 2006-06-13 2006-07-26 Novartis Ag Organic compounds
GB0611696D0 (en) 2006-06-13 2006-07-26 Novartis Ag Organic compounds
TW200831463A (en) 2006-09-12 2008-08-01 Speedel Experimenta Ag Nitrate esters of aminoalcohols
EP1908471A1 (en) 2006-10-04 2008-04-09 Speedel Experimenta AG Tetrahydropyridines as renin inhibitors
EP1921069A1 (de) 2006-11-08 2008-05-14 Speedel Experimenta AG Verfahren zur Herstellung von 2-Alkyl-3-heterocyclyl-prop-2-en-1-olen
WO2008113835A1 (en) 2007-03-21 2008-09-25 Novartis Ag Process for preparing (r or s)-5-{1-azido-3-[6-methoxy-5-(3-methoxy-propoxy)-pyridin-3-ylmethyl]-4-methyl-pentyl}-3-alkyl-dihydro-furan-2-one
BRPI0813900A2 (pt) 2007-06-25 2014-12-30 Novartis Ag Derivados de n5-(2-etoxietil)-n3-(2-piridinil)-3,5-piperidinodicarboxa mida para uso como inibidores de renina

Also Published As

Publication number Publication date
KR20100023003A (ko) 2010-03-03
BRPI0813900A2 (pt) 2014-12-30
NZ582098A (en) 2012-03-30
TN2009000530A1 (en) 2011-03-31
US8383650B2 (en) 2013-02-26
ECSP099825A (es) 2010-01-29
TWI404714B (zh) 2013-08-11
US20080319018A1 (en) 2008-12-25
CU20090226A7 (es) 2012-02-15
US8497286B2 (en) 2013-07-30
EP2181105B1 (en) 2015-04-29
KR101238479B1 (ko) 2013-03-04
EP2527338B1 (en) 2015-05-06
EP2181105A1 (en) 2010-05-05
AU2008267287B2 (en) 2012-02-16
JP5086433B2 (ja) 2012-11-28
CU23842B1 (es) 2012-10-15
CO6251267A2 (es) 2011-02-21
WO2009000811A1 (en) 2008-12-31
AU2008267287A1 (en) 2008-12-31
CA2689109A1 (en) 2008-12-31
EA016446B1 (ru) 2012-05-30
CL2008001872A1 (es) 2009-02-20
ES2543641T3 (es) 2015-08-20
CR11153A (es) 2010-01-21
PE20090425A1 (es) 2009-05-12
SG182223A1 (en) 2012-07-30
GT200900324A (es) 2011-11-03
ES2541107T3 (es) 2015-07-16
TW200911782A (en) 2009-03-16
EP2527338A1 (en) 2012-11-28
EA201000037A1 (ru) 2010-06-30
IL202494A0 (en) 2010-06-30
CN101687847B (zh) 2013-11-06
MA31538B1 (fr) 2010-07-01
US20130005770A1 (en) 2013-01-03
CN101687847A (zh) 2010-03-31
AR067132A1 (es) 2009-09-30
JP2010531328A (ja) 2010-09-24

Similar Documents

Publication Publication Date Title
CR10091A (es) Compuestos orgánicos
GT201300080A (es) Proceso de elaboracion para derivados de pirimidina
SV2011003939A (es) Piridiloxi-indoles inhibidores del vegf-r2 y uso de los mismos para el tratamiento de enfermedades
UY28757A1 (es) Compuestos de pirazolina substituidos, su preparación y su uso como medicamentos
EA201300121A1 (ru) Ингибитор дпп-4 в комбинации с дополнительным противодиабетическим агентом, таблетки, включающие указанные композиции, их применение и способ их получения
EA201100335A1 (ru) Производные пурина для применения при лечении связанных с fab заболеваний
EA201290078A1 (ru) Гетероциклические соединения для ингибирования pask
PA8748101A1 (es) Benzoxazoles y oxazolopiridinas que son utiles como inhibidores de las cinasas janus
ECSP088217A (es) Formas de cristal delta y épsilon de mesilato de imatinib
BRPI0811436A2 (pt) Composto, uso de um composto, composição farmacêutica, e, metódos para a terapia da dor em um animal de sangue quente, para a terapia da bexiga super ativa em um animal de sangue quente, e para preparar um composto.
NI201000044A (es) Bromhidrato de bupropión y aplicaciones terapéuticas
CL2010000188A1 (es) Metodo para el tratamiento de una infeccion en un sujeto que comprende la administracion de 9-[(2,2-dimetil-propilamino)-metil]-minociclina o de una sal de la misma; composicion farmaceutica que comprende dicho compuesto; y su uso.
GT200800148A (es) Agente terapéutico para la enfermedad inflamatoria intestinal conteniendo como ingrediente activo un derivado de 2-amino-1,3-propanediol o un método para el tratamiento de la enfermedad inflamatoria intestinal.
NI200800169A (es) Uso de derivados de sulfamidas heterocíclicas benzo-fusionadas para el tratamiento del dolor
ECSP088821A (es) Derivados de tioxantina y su uso como inhibidores de la mpo
CL2008001297A1 (es) N-[(1s)-1-(5-fluoropirim idin-2-i1 )etil]-3-(5-isopropoxi-1 h-pirazol-3-il )-3h-imidazo[4,5-b]piridin-5amina o una sal farmacéuticamente aceptabie del mismo; composición farmacéutica que lo comprende; y su uso en el tratamiento del cáncer.
UY30158A1 (es) Uso de derivados de benzo-heteroaril sulfamida para el tratamiento del dolor
NI201000015A (es) Bromhidrato de bupropión y aplicaciones terapéuticas
GT200600089A (es) Compuestos organicos
CU20120081A7 (es) Nuevas formas polimorfas de {4,6-diamino-2-[1-(2-fluorobencil)-1h-pirazolo[3,4-b]piridin-3-il]pirimidin-5-il}carbamato de metilo
ECSP10010464A (es) Uso de ranolazina para el tratamiento de enfermedades cardiovasculares
HN2009003463A (es) Derivados de n5-(2-etoxi-etil)-n3-(2- piridinil) -3,5- piperidin-dicarboxamida para usarse como inhibidores de renina
AR052322A1 (es) Compuestos de n-benzoil-estaurosporina, procesos para su preparacion y composicion farmaceutica
AR058173A1 (es) Uso de sdf-1 para el tratamiento y/o prevencion de enfermedades neurologicas
NI201000096A (es) TRATAMIENTO DE CARDIOPATÍAS USANDO Beta-BLOQUEANTES.